CN112442128B - 抗磷脂酶d4抗体 - Google Patents

抗磷脂酶d4抗体 Download PDF

Info

Publication number
CN112442128B
CN112442128B CN202011128007.3A CN202011128007A CN112442128B CN 112442128 B CN112442128 B CN 112442128B CN 202011128007 A CN202011128007 A CN 202011128007A CN 112442128 B CN112442128 B CN 112442128B
Authority
CN
China
Prior art keywords
seq
antibody
pld4
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011128007.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112442128A (zh
Inventor
赵民权
山崎智英
远藤真由木
石田晃司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112442128(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Priority to CN202011128007.3A priority Critical patent/CN112442128B/zh
Publication of CN112442128A publication Critical patent/CN112442128A/zh
Application granted granted Critical
Publication of CN112442128B publication Critical patent/CN112442128B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202011128007.3A 2012-01-31 2013-01-31 抗磷脂酶d4抗体 Active CN112442128B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011128007.3A CN112442128B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012018266 2012-01-31
JP2012-018266 2012-01-31
CN201380018285.5A CN104284903B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体
CN202011128007.3A CN112442128B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体
PCT/JP2013/052781 WO2013115410A2 (en) 2012-01-31 2013-01-31 Anti-phospholipase d4 antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380018285.5A Division CN104284903B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体

Publications (2)

Publication Number Publication Date
CN112442128A CN112442128A (zh) 2021-03-05
CN112442128B true CN112442128B (zh) 2024-05-17

Family

ID=47748721

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011128007.3A Active CN112442128B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体
CN201380018285.5A Active CN104284903B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380018285.5A Active CN104284903B (zh) 2012-01-31 2013-01-31 抗磷脂酶d4抗体

Country Status (15)

Country Link
US (2) US9944715B2 (enExample)
EP (2) EP2809683B1 (enExample)
JP (4) JP6118345B2 (enExample)
KR (1) KR102098413B1 (enExample)
CN (2) CN112442128B (enExample)
AU (2) AU2013215886B2 (enExample)
CA (1) CA2863009C (enExample)
DK (2) DK2809683T3 (enExample)
ES (2) ES2694165T3 (enExample)
HU (2) HUE041552T2 (enExample)
IL (1) IL233794B (enExample)
PL (2) PL3431504T3 (enExample)
PT (1) PT2809683T (enExample)
TR (1) TR201819828T4 (enExample)
WO (1) WO2013115410A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
WO2015016386A1 (en) * 2013-07-30 2015-02-05 Sbi Biotech Co., Ltd. Medicament comprising anti-phospholipase d4 antibody
BR112016014920A2 (pt) * 2013-12-24 2017-12-12 Astellas Pharma Inc novo anticorpo anti-bdca-2 humano
EP3402520A4 (en) 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
SG10202008769SA (en) * 2016-03-10 2020-10-29 Viela Bio Inc Ilt7 binding molecules and methods of using the same
CN105624325B (zh) * 2016-03-31 2019-06-11 北京泱深生物信息技术有限公司 肺腺癌的诊治标记物
ES2864013T3 (es) * 2017-10-14 2021-10-13 Abbvie Inc Conjugados de fármaco y anticuerpo activable anti-CD71 y métodos de uso de los mismos
CN110042123B (zh) * 2019-01-07 2023-01-17 西北农林科技大学 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法
WO2025085746A1 (en) * 2023-10-18 2025-04-24 Immunorx Pharma Inc. Humanized anti-s100a9 antibody
CN119120388A (zh) * 2024-10-22 2024-12-13 江苏亲科生物研究中心有限公司 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842540A (zh) * 2004-07-09 2006-10-04 中外制药株式会社 抗－磷脂酰肌醇蛋白聚糖3抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098015B2 (en) * 1999-06-11 2006-08-29 Millennium Pharmaceuticals, Inc. 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
CN1878795A (zh) 2002-12-02 2006-12-13 阿布格尼克斯公司 针对磷脂酶a2的抗体及其应用
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
WO2015016386A1 (en) * 2013-07-30 2015-02-05 Sbi Biotech Co., Ltd. Medicament comprising anti-phospholipase d4 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842540A (zh) * 2004-07-09 2006-10-04 中外制药株式会社 抗－磷脂酰肌醇蛋白聚糖3抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Phospholipase D Family Member 4, a Transmembrane Glycoprotein with No Phospholipase D Activity, Expression in Spleen and Early Postnatal Microglia;YOSHIKAWA等;《PLOS ONE》;第5卷(第11期);第e13932页 *
PLD4 Is Involved in Phagocytosis of Microglia: Expression and Localization Changes of PLD4 Are Correlated with Activation State of Microglia;OTANI等;《PLOS ONE》;第6卷(第11期);第e27544页 *

Also Published As

Publication number Publication date
JP7244102B2 (ja) 2023-03-22
PT2809683T (pt) 2019-01-17
CN112442128A (zh) 2021-03-05
WO2013115410A3 (en) 2013-09-26
PL3431504T3 (pl) 2021-10-18
JP6118345B2 (ja) 2017-04-19
HUE054362T2 (hu) 2021-09-28
IL233794B (en) 2021-04-29
IL233794A0 (en) 2014-09-30
JP2019048874A (ja) 2019-03-28
HUE041552T2 (hu) 2019-05-28
CN104284903A (zh) 2015-01-14
EP2809683B1 (en) 2018-10-03
BR112014018539A8 (pt) 2017-07-11
US10336834B2 (en) 2019-07-02
DK2809683T3 (en) 2018-12-10
CN104284903B (zh) 2020-10-09
JP2017155045A (ja) 2017-09-07
US9944715B2 (en) 2018-04-17
BR112014018539A2 (enExample) 2017-06-20
JP2015508056A (ja) 2015-03-16
DK3431504T3 (da) 2021-06-28
EP3431504B1 (en) 2021-03-24
ES2694165T3 (es) 2018-12-18
AU2013215886B2 (en) 2017-11-09
EP2809683A2 (en) 2014-12-10
AU2018200934A1 (en) 2018-03-01
CA2863009C (en) 2020-07-07
AU2013215886A1 (en) 2014-08-14
JP2021019630A (ja) 2021-02-18
CA2863009A1 (en) 2013-08-08
TR201819828T4 (tr) 2019-01-21
KR102098413B1 (ko) 2020-04-07
EP3431504A1 (en) 2019-01-23
US20180258185A1 (en) 2018-09-13
US20150044226A1 (en) 2015-02-12
KR20140126337A (ko) 2014-10-30
ES2873035T3 (es) 2021-11-03
AU2018200934B2 (en) 2019-09-12
JP6830471B2 (ja) 2021-02-17
PL2809683T3 (pl) 2019-03-29
WO2013115410A2 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
CN112442128B (zh) 抗磷脂酶d4抗体
AU2015314316B2 (en) Cross reactive Siglec antibodies
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
JP7036729B2 (ja) 治療用抗ｃｄ９抗体
HK1218126A1 (zh) 抗ilt7抗体
JP6843449B2 (ja) 抗ホスホリパーゼｄ４抗体を含む医薬
JP2021530511A (ja) 抗ｐｄ−１抗体、投薬量、およびその使用
TWI862019B (zh) 治療性ｃｄ２４人類化單株抗體及抗腫瘤轉譯應用
HK40039509A (en) Anti-phospholipase d4 antibody
HK40039509B (zh) 抗磷脂酶d4抗体
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
JP2022517313A (ja) 抗ｏｘ４０モノクローナル抗体とその応用
BR112014018539B1 (pt) Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039509

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant